ATHA Stock Summary and Trading Ideas (Athira Pharma | NASDAQ:ATHA)

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Athira Pharma trades on the NASDAQ stock market under the symbol ATHA.

As of January 16, 2026, ATHA stock price was flat at $6.75 with million shares trading.

ATHA has a beta of 2.07, meaning it tends to be more sensitive to market movements. ATHA has a correlation of 0.15 to the broad based SPY ETF.

ATHA has a market cap of $26.62 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, ATHA traded as high as $44.10 and as low as $2.20.

ATHA has outperformed the market in the last year with a return of +27.1%, while the SPY ETF gained +18.1%. In the last 3 month period, ATHA beat the market returning +84.4%, while SPY returned +5.0%. However, in the most recent 2 weeks ATHA has underperformed the stock market by returning -3.0%, while SPY returned +1.2%.

ATHA support price is $6.32 and resistance is $7.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATHA shares will trade within this expected range on the day.